Neurocrine Biosciences
NBIX
223 hedge funds and large institutions have $5.88B invested in Neurocrine Biosciences in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 98 increasing their positions, 51 reducing their positions, and 27 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 51
61% more call options, than puts
Call options by funds: $37.3M | Put options by funds: $23.2M
35% more capital invested
Capital invested by funds: $4.36B → $5.88B (+$1.52B)
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
1.1% more ownership
Funds ownership: 107.69% → 108.79% (+1.1%)
1% more funds holding
Funds holding: 221 → 223 (+2)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$64.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$31.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$31.1M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$53.7M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$34.5M |
| 3 |
HM
HealthCor Management
New York
|
-$24.4M |
| 4 |
Bank of New York Mellon
New York
|
-$18.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.4M |
NBIX Hedge Fund Activity: Q3 2017 in Review
223 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2017, worth a combined $5.88B — up 35% from $4.36B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new NBIX positions and 27 closed out — a net gain of 6 holders — while 98 added to existing stakes and 51 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $64.1M. The largest seller was Westfield Capital Management, cutting an estimated $53.7M.
- 223 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2017, up from 221 in Q2 2017.
- Funds reported $5.88B of Neurocrine Biosciences stock for Q3 2017, up 35% quarter-over-quarter.
- 33 funds opened new Neurocrine Biosciences positions in Q3 2017 and 27 closed out, a net change of +6 holders.
- The largest Neurocrine Biosciences buyer in Q3 2017 was Perceptive Advisors, an estimated $64.1M added.
- The largest Neurocrine Biosciences seller in Q3 2017 was Westfield Capital Management, an estimated $53.7M sold.
Based on aggregated 13F filings for Q3 2017.